Paul P. Cook, M.D.
Professor of Medicine
Chief, Division of Infectious Diseases
Division of Infectious Diseases
Education:
Undergraduate:BS Biochemistry,University of Georgia, Athens, Georgia, 1978
Medical School: M.D., Medical College of Georgia, Augusta, GA 1982
Training:
Residency: North Carolina Memorial Hospital, Chapel Hill, NC 1985
Fellowship: Tufts-New England Medical Center, Boston, MA 1988, Infectious Diseases
Areas of Interest:
Antibiotic Management, Clostridium difficile, Tuberculosis
Recent Publications/Abstracts:
-
Dr. Paul Cook - Gooch M, Rizzo, S. Reduction in fluoroquinolone use following introduction of ertapenem to hospital formulary associated with improvement in susceptibility of Pseudomonas aeruginosa to group 2 carbapenems: a 10-year study. Antimicrob Agents Chemother. 2011;55:5597-5601.
-
Lewis GJ, Gooch M, Fang X, Cook PP. Decreased resistance of Pseudomonas aeruginosa with restriction of ciprofloxacin in a large teaching hospital’s intensive and intermediate care units. Infect Control Hosp Epidemiol. 2012;33:368-73.
-
Dyson OF, Walker LR, Whitehouse A, Cook PP, Akula SM. Resveratrol inhibits KSHV reactivation by lowering the levels of cellular EGR-1. PLoSONE. 2012;7(3): e33364. doi:10.1371/journal.pone.0033364.
-
O’Neal, W, Fang X, Winters M, Augustino K, Cook PP. TB Screening in an HIV Clinic: How Interferon-γ Assays Improve Screening Compliance. Int J Tuber Lung Dis. 2012;16:707.
-
Riaawi, R., Kabchi, B., Ashraf, M. S. , Mazer, M., Gooch, M., P Cook, (2012). A REVIEW OF ANTIMICROBIAL USE IN THE MEDICAL ICU - A NEED FOR IMPROVEMENT? 26th Annual Yash P. Kataria Research Day, Greenville, North Carolina.
